touchCONGRESS

PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education
Gynaecological Oncology, Ovarian Cancer Watch Time: 61 mins

touchCONGRESS PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice

Watch this two-part activity exploring recent developments on the use of PARP inhibitors as first-line maintenance therapy in ovarian cancer. Filmed following the SGO Virtual Annual Meeting 2021.

Part 1: Watch gynaecological cancer expert Dr Alexandra Leary review key data from the SGO Virtual Annual Meeting 2021 Watch Now
Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview

  • Part 1: Data Review
Next Chapter
Introduction
Update on PARP inhibitors as first-line maintenance therapy
Emerging real-world outcomes with PARP inhibitors
Factors guiding treatment decisions surrounding PARP inhibitors in first-line maintenance therapy
Video Player Controls:
 
Leave Feedback
Overview

Watch Dr Alexandra Leary summarize and share her interpretation of the latest data from SGO Virtual 2021 on the use of PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer. During the presentation she considers:

  • Data from subgroup analyses of the first-line maintenance treatment trials
  • What we can learn from real-world use of PARP inhibitors in ovarian cancer
  • New information to guide the use of PARP inhibitors in the clinic
About Dr Alexandra Leary

Alexandra Leary is a Medical Oncologist and Translational Researcher specializing in gynaecological tumours at Gustave Roussy, with a special focus on early phase drug development. Dr Leary is also team leader for gynaecological oncology translational research within the laboratory of Predictive Biomarkers and Novel Targeted Therapeutics (INSERM U981) at Gustave Roussy. read more

Nationally, she sits on the board of the French clinical trial intergroup, GINECO, and is President of the GINECO Group on Early Phase Studies (GINEGEPS). Internationally, she is a member of the ENGOT (European Network of Gynaecological Oncological Trial groups) translational research group, French representative at the Gynecologic Cancer InterGroup (GCIG), co-Chair of the GCIG phase II trial group, European Society for Medical Oncology (ESMO) faculty and gynaecology track Chair.

Alexandra Leary discloses: Personal fees from Ability, AstraZeneca, BIOCAD, Clovis Oncology, GlaxoSmithKline, Merck Serono, Merck Sharp & Dohme, Seattle Genetics, Tesaro and Zentalis. Grant support from Ability, AstraZeneca, Clovis Oncology, GlaxoSmithKline, Merck Sharp & Dohme and Tesaro. Non-financial support from AstraZeneca, Clovis Oncology, GlaxosmithKline and Tesaro. Other support from GlaxoSmithKline and Merck Serono.

Downloads

View and download resources from this activity to support your learning or share with colleagues

  • Part 2: Expert Interviews
Leave Feedback
Prof. Nicoletta Colombo
Watch Time: 12:20
University of Milan-Bicocca, Milan, Italy

Nicoletta Colombo considers the latest data on PARP inhibitors as first-line maintenance therapy in advanced ovarian cancer, presented at SGO Virtual 2021.

 
 
Leave Feedback
Interview Questions

In this interview, Prof. Colombo answers the following questions:

  • How do the results from the OVARIO trial add to our knowledge of PARP inhibition plus bevacizumab for first-line maintenance in ovarian cancer?
  • Five-year follow-up data from SOLO-1 were presented at SGO Virtual 2021. How will these data impact the use of PARP inhibitor monotherapy as first-line maintenance?
  • What does the analysis from PRIMA, exploring niraparib efficacy by timing of surgery and residual disease, mean for clinical practice?
  • What are the key learnings from the real-world evidence for PARP inhibitor maintenance treatment presented at SGO Virtual 2021?
  • What do analyses presented at SGO Virtual 2021 tell us about selecting the most appropriate first-line maintenance treatment for individual patients?
About Prof. Nicoletta Colombo

Nicoletta Colombo is Associate Professor of Obstetrics and Gynaecology at the University of Milan-Bicocca, Italy. She is also Director of the Medical Gynaecologic Oncology Division of the European Institute of Oncology, Milan, Italy. read more

Prof. Colombo is a principal investigator for several international clinical trials, and has authored many publications in the field of gynaecologic oncology. From 2016 to 2020, she was Subject Editor of the European Society for Medical Oncology (ESMO) clinical guidelines for gynaecological malignancies. She is Past-President of the European Society of Gynaecologic Oncology (ESGO) and was Chair of the first ESMO–ESGO Consensus Conference in ovarian Cancer (2018).

Nicoletta Colombo discloses: Speaker fees from AstraZeneca, Novartis and Tesaro. Advisory board fees from AstraZeneca, BIOCAD, Clovis Oncology, Eisai, GlaxoSmithKline, Immunogen, Merck Sharp & Dohme, Mersana, Novartis, Pharmamar, Pfizer, Roche, Takeda and Tesaro.

Prof. Keiichi Fujiwara
Watch Time: 08:47
Saitama Medical University International Medical Center, Saitama, Japan

Keiichi Fujiwara considers the latest data on PARP inhibitors as first-line maintenance therapy in advanced ovarian cancer, presented at SGO Virtual 2021.

 

 
 
Leave Feedback
Interview Questions

In this interview, Prof. Fujiwara answers the following questions:

  • How do the results from the OVARIO trial add to our knowledge of PARP inhibition plus bevacizumab for first-line maintenance in ovarian cancer?
  • Five-year follow-up data from SOLO-1 were presented at SGO Virtual 2021. How will these data impact the use of PARP inhibitor monotherapy as first-line maintenance?
  • What does the analysis from PRIMA, exploring niraparib efficacy by timing of surgery and residual disease, mean for clinical practice?
  • What are the key learnings from the real-world evidence for PARP inhibitor maintenance treatment presented at SGO Virtual 2021?
  • What do analyses presented at SGO Virtual 2021 tell us about selecting the most appropriate first-line maintenance treatment for individual patients?
About Prof. Keiichi Fujiwara

Keiichi Fujiwara is Deputy Director of the Saitama Medical University International Medical Center, Japan, where he also chairs the Department of Gynecologic Oncology. He is an Associate Professor in the Department of Obstetrics and Gynecology at Kawasaki Medical School, Kurashiki-City, Japan. read more

Prof. Fujiwara is currently President Elect of the International Gynecologic Cancer Society (IGCS) and is a member of the Ovarian Cancer Task Force within the Gynecologic Cancer Steering Committee of the US National Cancer Institute.

Prof. Fujiwara’s main interests encompass surgery and chemotherapy in various gynaecological malignancies. He is a Principal Investigator of NRG Oncology/Gynecologic Oncology Group (GOG) Japan, which is an international member of NRG Oncology/GOG US, and founding member and Vice Chair of the Gynecologic Oncology Trial and Investigation Consortium.

Keiichi Fujiwara discloses: Speaker fees from AstraZeneca, Merck Sharp & Dohme and Takeda. Research support from AstraZeneca, Merck Sharp & Dohme and Takeda. Advisory Board fees from Merck Sharp & Dohme.

Dr Alexandra Leary
Watch Time: 09:33
Gustave Roussy, Villejuif, France

Alexandra Leary considers the latest data on PARP inhibitors as first-line maintenance therapy in advanced ovarian cancer, presented at SGO Virtual 2021.

 
 
Leave Feedback
Interview Questions

In this interview, Dr Leary answers the following questions:

  • How do the results from the OVARIO trial add to our knowledge of PARP inhibition plus bevacizumab for first-line maintenance in ovarian cancer?
  • Five-year follow-up data from SOLO-1 were presented at SGO Virtual 2021. How will these data impact the use of PARP inhibitor monotherapy as first-line maintenance?
  • What does the analysis from PRIMA, exploring niraparib efficacy by timing of surgery and residual disease, mean for clinical practice?
  • What are the key learnings from the real-world evidence for PARP inhibitor maintenance treatment presented at SGO Virtual 2021?
  • What do analyses presented at SGO Virtual 2021 tell us about selecting the most appropriate first-line maintenance treatment for individual patients?
About Dr Alexandra Leary

Alexandra Leary is a Medical Oncologist and Translational Researcher specializing in gynaecological tumours at Gustave Roussy, with a special focus on early phase drug development. Dr Leary is also team leader for gynaecological oncology translational research within the laboratory of Predictive Biomarkers and Novel Targeted Therapeutics (INSERM U981) at Gustave Roussy. read more

Nationally, she sits on the board of the French clinical trial intergroup, GINECO, and is President of the GINECO Group on Early Phase Studies (GINEGEPS). Internationally, she is a member of the ENGOT (European Network of Gynaecological Oncological Trial groups) translational research group, French representative at the Gynecologic Cancer InterGroup (GCIG), co-Chair of the GCIG phase II trial group, European Society for Medical Oncology (ESMO) faculty and gynaecology track Chair.

Alexandra Leary discloses: Personal fees from Ability, AstraZeneca, BIOCAD, Clovis Oncology, GlaxoSmithKline, Merck Serono, Merck Sharp & Dohme, Seattle Genetics, Tesaro and Zentalis. Grant support from Ability, AstraZeneca, Clovis Oncology, GlaxoSmithKline, Merck Sharp & Dohme and Tesaro. Non-financial support from AstraZeneca, Clovis Oncology, GlaxosmithKline and Tesaro. Other support from GlaxoSmithKline and Merck Serono.

Please Select A Video:
Leave Feedback
Overview & Learning Objectives
Overview

Get an update on the use of PARP inhibitors as first-line maintenance treatment for ovarian cancer in this two-part activity. Filmed following the SGO Virtual Annual Meeting 2021.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recall the latest data for PARP inhibitors for first-line maintenance treatment and how they may impact clinical practice
  • Describe the latest safety data for the PARP inhibitors
  • Define the different factors that influence treatment selection of PARP inhibitor therapy in the first-line maintenance setting
Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions.
  • Interactive CME and e-learning modules.
  • Video conference highlights.
Register For Free Now

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchCONGRESS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72